ID   UBE4B_HUMAN             Reviewed;        1302 AA.
AC   O95155; A8K8S9; G0ZJH6; O75169; O95338; Q5SZ12; Q5SZ16; Q96QD4; Q9BYI7;
DT   01-NOV-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   28-JUN-2023, entry version 192.
DE   RecName: Full=Ubiquitin conjugation factor E4 B {ECO:0000305};
DE            EC=2.3.2.27 {ECO:0000250|UniProtKB:Q9ES00};
DE   AltName: Full=Homozygously deleted in neuroblastoma 1 {ECO:0000312|EMBL:BAB40446.1};
DE   AltName: Full=RING-type E3 ubiquitin transferase E4 B;
DE   AltName: Full=Ubiquitin fusion degradation protein 2 {ECO:0000312|EMBL:AAD02233.1};
GN   Name=UBE4B {ECO:0000312|HGNC:HGNC:12500};
GN   Synonyms=HDNB1 {ECO:0000312|EMBL:BAB40446.1}, KIAA0684
GN   {ECO:0000312|EMBL:BAA31659.3}, UFD2 {ECO:0000312|EMBL:AAD02233.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=9653645; DOI=10.1006/geno.1997.5186;
RA   Onyango P., Lubyova B., Gardellin P., Kurzbauer R., Weith A.;
RT   "Molecular cloning and expression analysis of five novel genes in
RT   chromosome 1p36.";
RL   Genomics 50:187-198(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Substantia nigra;
RX   PubMed=10980605; DOI=10.1038/sj.onc.1203786;
RA   Ohira M., Kageyama H., Mihara M., Furuta S., Machida T., Shishikura T.,
RA   Takayasu H., Islam A., Nakamura Y., Takahashi M., Tomioka N., Sakiyama S.,
RA   Kaneko Y., Toyoda A., Hattori M., Sakaki Y., Ohki M., Horii A., Soeda E.,
RA   Inazawa J., Seki N., Kuma H., Nozawa I., Nakagawara A.;
RT   "Identification and characterization of a 500-kb homozygously deleted
RT   region at 1p36.2-p36.3 in a neuroblastoma cell line.";
RL   Oncogene 19:4302-4307(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY, MUTAGENESIS OF
RP   ASP-109; ASP-121 AND ASP-123, AND CLEAVAGE BY CASPASES.
RX   PubMed=11802788; DOI=10.1042/0264-6021:3610587;
RA   Mahoney J.A., Odin J.A., White S.M., Shaffer D., Koff A.,
RA   Casciola-Rosen L., Rosen A.;
RT   "The human homologue of the yeast polyubiquitination factor Ufd2p is
RT   cleaved by caspase 6 and granzyme B during apoptosis.";
RL   Biochem. J. 361:587-595(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), AND ALTERNATIVE SPLICING.
RC   TISSUE=Skeletal muscle;
RX   PubMed=22174917; DOI=10.1371/journal.pone.0028861;
RA   Mammen A.L., Mahoney J.A., St Germain A., Badders N., Taylor J.P.,
RA   Rosen A., Spinette S.;
RT   "A novel conserved isoform of the ubiquitin ligase UFD2a/UBE4B is expressed
RT   exclusively in mature striated muscle cells.";
RL   PLoS ONE 6:E28861-E28861(2011).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=9734811; DOI=10.1093/dnares/5.3.169;
RA   Ishikawa K., Nagase T., Suyama M., Miyajima N., Tanaka A., Kotani H.,
RA   Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. X. The
RT   complete sequences of 100 new cDNA clones from brain which can code for
RT   large proteins in vitro.";
RL   DNA Res. 5:169-176(1998).
RN   [6]
RP   SEQUENCE REVISION.
RA   Ohara O., Suyama M., Nagase T., Ishikawa K.;
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Cerebellum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1112-1302.
RA   Barrow I.K.-P., Boguski M.S., Touchman J.W., Spencer F.;
RT   "Full-insert sequence of mapped XREF EST.";
RL   Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-803, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-31, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [13]
RP   FUNCTION, INTERACTION WITH VCP; STUB1 AND UNC45B, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=17369820; DOI=10.1038/ncb1554;
RA   Janiesch P.C., Kim J., Mouysset J., Barikbin R., Lochmueller H.,
RA   Cassata G., Krause S., Hoppe T.;
RT   "The ubiquitin-selective chaperone CDC-48/p97 links myosin assembly to
RT   human myopathy.";
RL   Nat. Cell Biol. 9:379-390(2007).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-803, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-31; SER-88; SER-90; SER-101
RP   AND SER-803, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-84; SER-88; SER-90 AND
RP   SER-101, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-803 AND SER-1265, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-103 AND SER-803, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [22]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [23]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-23; SER-31; SER-101; SER-105;
RP   SER-124; SER-238; SER-383; SER-803 AND SER-1265, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-88, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Ubiquitin-protein ligase that probably functions as an E3
CC       ligase in conjunction with specific E1 and E2 ligases (By similarity).
CC       May also function as an E4 ligase mediating the assembly of
CC       polyubiquitin chains on substrates ubiquitinated by another E3
CC       ubiquitin ligase (By similarity). May regulate myosin assembly in
CC       striated muscles together with STUB1 and VCP/p97 by targeting myosin
CC       chaperone UNC45B for proteasomal degradation (PubMed:17369820).
CC       {ECO:0000250|UniProtKB:P54860, ECO:0000250|UniProtKB:Q9ES00,
CC       ECO:0000269|PubMed:17369820}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.27; Evidence={ECO:0000250|UniProtKB:Q9ES00};
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000250|UniProtKB:Q9ES00}.
CC   -!- SUBUNIT: Interacts with VCP/p97. Interacts with STUB1/CHIP and UNC45B.
CC       {ECO:0000269|PubMed:17369820}.
CC   -!- INTERACTION:
CC       O95155-1; P62837: UBE2D2; NbExp=2; IntAct=EBI-15869194, EBI-347677;
CC       O95155-1; P61077-1: UBE2D3; NbExp=3; IntAct=EBI-15869194, EBI-15567256;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17369820}. Nucleus
CC       {ECO:0000250|UniProtKB:Q9ES00}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=O95155-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O95155-2; Sequence=VSP_007102;
CC       Name=3;
CC         IsoId=O95155-3; Sequence=VSP_007101, VSP_007102, VSP_007103;
CC       Name=4; Synonyms=UFD2a-7/7a, UFD2A-III;
CC         IsoId=O95155-4; Sequence=VSP_053372;
CC   -!- TISSUE SPECIFICITY: Expressed in differentiated myotubes (at protein
CC       level) (PubMed:17369820). Highest expression in ovary, testis, heart
CC       and skeletal muscle (PubMed:11802788). Expression is low in colon,
CC       thymus and peripheral blood leukocytes (PubMed:11802788). Almost
CC       undetectable in lung and spleen (PubMed:11802788).
CC       {ECO:0000269|PubMed:11802788, ECO:0000269|PubMed:17369820}.
CC   -!- DOMAIN: The U-box domain is required for the ubiquitin protein ligase
CC       activity. {ECO:0000250|UniProtKB:Q9ES00}.
CC   -!- PTM: Proteolytically cleaved by caspases during apoptosis. Cleaved
CC       efficiently at Asp-123 by caspase-6 and granzyme B. Cleaved with
CC       approximately 10-fold less efficiency at Asp-109 by caspase-3 and
CC       caspase-7. {ECO:0000269|PubMed:11802788}.
CC   -!- MISCELLANEOUS: [Isoform 4]: Expressed exclusively in mature striated
CC       muscle cells. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the ubiquitin conjugation factor E4 family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA31659.3; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF043117; AAD02233.1; -; mRNA.
DR   EMBL; AB028839; BAB40446.1; -; mRNA.
DR   EMBL; AF331520; AAK69622.1; -; mRNA.
DR   EMBL; JF289274; AEK06331.1; -; mRNA.
DR   EMBL; AB014584; BAA31659.3; ALT_INIT; mRNA.
DR   EMBL; AK292444; BAF85133.1; -; mRNA.
DR   EMBL; AL096841; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL590639; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC093696; AAH93696.1; -; mRNA.
DR   EMBL; AF091093; AAC72962.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS110.1; -. [O95155-2]
DR   CCDS; CCDS41245.1; -. [O95155-1]
DR   CCDS; CCDS90857.1; -. [O95155-4]
DR   PIR; T00358; T00358.
DR   RefSeq; NP_001099032.1; NM_001105562.2. [O95155-1]
DR   RefSeq; NP_006039.2; NM_006048.4. [O95155-2]
DR   RefSeq; XP_005263479.1; XM_005263422.1.
DR   PDB; 2KRE; NMR; -; A=1208-1302.
DR   PDB; 3L1X; X-ray; 2.60 A; A=1208-1302.
DR   PDB; 3L1Z; X-ray; 3.17 A; B=1208-1302.
DR   PDB; 5O75; X-ray; 1.48 A; A=1226-1302.
DR   PDBsum; 2KRE; -.
DR   PDBsum; 3L1X; -.
DR   PDBsum; 3L1Z; -.
DR   PDBsum; 5O75; -.
DR   AlphaFoldDB; O95155; -.
DR   SMR; O95155; -.
DR   BioGRID; 115566; 125.
DR   DIP; DIP-40309N; -.
DR   IntAct; O95155; 15.
DR   MINT; O95155; -.
DR   STRING; 9606.ENSP00000343001; -.
DR   GlyGen; O95155; 2 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; O95155; -.
DR   PhosphoSitePlus; O95155; -.
DR   BioMuta; UBE4B; -.
DR   EPD; O95155; -.
DR   jPOST; O95155; -.
DR   MassIVE; O95155; -.
DR   MaxQB; O95155; -.
DR   PaxDb; O95155; -.
DR   PeptideAtlas; O95155; -.
DR   ProteomicsDB; 50670; -. [O95155-1]
DR   ProteomicsDB; 50671; -. [O95155-2]
DR   ProteomicsDB; 50672; -. [O95155-3]
DR   Antibodypedia; 13520; 206 antibodies from 31 providers.
DR   DNASU; 10277; -.
DR   Ensembl; ENST00000253251.12; ENSP00000253251.8; ENSG00000130939.20. [O95155-2]
DR   Ensembl; ENST00000343090.11; ENSP00000343001.6; ENSG00000130939.20. [O95155-1]
DR   Ensembl; ENST00000672724.1; ENSP00000500453.1; ENSG00000130939.20. [O95155-4]
DR   GeneID; 10277; -.
DR   KEGG; hsa:10277; -.
DR   MANE-Select; ENST00000343090.11; ENSP00000343001.6; NM_001105562.3; NP_001099032.1.
DR   UCSC; uc001aqr.5; human. [O95155-1]
DR   AGR; HGNC:12500; -.
DR   CTD; 10277; -.
DR   DisGeNET; 10277; -.
DR   GeneCards; UBE4B; -.
DR   HGNC; HGNC:12500; UBE4B.
DR   HPA; ENSG00000130939; Low tissue specificity.
DR   MalaCards; UBE4B; -.
DR   MIM; 613565; gene.
DR   neXtProt; NX_O95155; -.
DR   OpenTargets; ENSG00000130939; -.
DR   Orphanet; 1606; 1p36 deletion syndrome.
DR   PharmGKB; PA37148; -.
DR   VEuPathDB; HostDB:ENSG00000130939; -.
DR   eggNOG; KOG2042; Eukaryota.
DR   GeneTree; ENSGT00390000009300; -.
DR   HOGENOM; CLU_003224_2_0_1; -.
DR   InParanoid; O95155; -.
DR   OMA; INKNAGR; -.
DR   OrthoDB; 1554at2759; -.
DR   PhylomeDB; O95155; -.
DR   TreeFam; TF300802; -.
DR   BRENDA; 2.3.2.27; 2681.
DR   BRENDA; 2.3.2.B12; 2681.
DR   PathwayCommons; O95155; -.
DR   SignaLink; O95155; -.
DR   SIGNOR; O95155; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 10277; 100 hits in 1202 CRISPR screens.
DR   ChiTaRS; UBE4B; human.
DR   EvolutionaryTrace; O95155; -.
DR   GeneWiki; UBE4B; -.
DR   GenomeRNAi; 10277; -.
DR   Pharos; O95155; Tbio.
DR   PRO; PR:O95155; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; O95155; protein.
DR   Bgee; ENSG00000130939; Expressed in buccal mucosa cell and 210 other tissues.
DR   ExpressionAtlas; O95155; baseline and differential.
DR   Genevisible; O95155; HS.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0000151; C:ubiquitin ligase complex; TAS:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; ISS:UniProtKB.
DR   GO; GO:0034450; F:ubiquitin-ubiquitin ligase activity; IBA:GO_Central.
DR   GO; GO:0008626; P:granzyme-mediated apoptotic signaling pathway; IDA:UniProtKB.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IDA:MGI.
DR   GO; GO:0000209; P:protein polyubiquitination; IBA:GO_Central.
DR   GO; GO:0009411; P:response to UV; IDA:UniProtKB.
DR   GO; GO:0030433; P:ubiquitin-dependent ERAD pathway; IBA:GO_Central.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; TAS:UniProtKB.
DR   CDD; cd16658; RING-Ubox_UBE4B; 1.
DR   Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1.
DR   InterPro; IPR019474; Ub_conjug_fac_E4_core.
DR   InterPro; IPR045132; UBE4.
DR   InterPro; IPR003613; Ubox_domain.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR13931:SF2; UBIQUITIN CONJUGATION FACTOR E4 B; 1.
DR   PANTHER; PTHR13931; UBIQUITINATION FACTOR E4; 1.
DR   Pfam; PF04564; U-box; 1.
DR   Pfam; PF10408; Ufd2P_core; 1.
DR   SMART; SM00504; Ubox; 1.
DR   SUPFAM; SSF57850; RING/U-box; 1.
DR   PROSITE; PS51698; U_BOX; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cytoplasm; Nucleus;
KW   Phosphoprotein; Reference proteome; Transferase; Ubl conjugation pathway.
FT   CHAIN           1..1302
FT                   /note="Ubiquitin conjugation factor E4 B"
FT                   /id="PRO_0000194993"
FT   DOMAIN          1227..1300
FT                   /note="U-box"
FT   REGION          1..155
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          299..406
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1057..1077
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1..15
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        31..45
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        49..123
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        129..151
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        299..331
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        338..373
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        386..406
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            109..110
FT                   /note="Cleavage; by caspase-3 and caspase-7"
FT   SITE            123..124
FT                   /note="Cleavage; by caspase-6 and granzyme B"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:22814378"
FT   MOD_RES         23
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         31
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163"
FT   MOD_RES         84
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         88
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:24275569"
FT   MOD_RES         90
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         101
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         103
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         105
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         124
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         238
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         383
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         803
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         969
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9ES00"
FT   MOD_RES         1265
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         1..116
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_007101"
FT   VAR_SEQ         270..398
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:10980605,
FT                   ECO:0000303|PubMed:11802788, ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:9734811"
FT                   /id="VSP_007102"
FT   VAR_SEQ         398
FT                   /note="P -> PSMYDNPFSFLFLALSGDSSDEEDEEEDDDDGDGDDEGGGGGDDFSC
FT                   VQFGS (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:22174917"
FT                   /id="VSP_053372"
FT   VAR_SEQ         1234
FT                   /note="D -> GKWTH (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_007103"
FT   VARIANT         605
FT                   /note="V -> I (in dbSNP:rs17034499)"
FT                   /id="VAR_052437"
FT   MUTAGEN         109
FT                   /note="D->A: Abolishes cleavage by caspase-3 and
FT                   caspase-7."
FT                   /evidence="ECO:0000269|PubMed:11802788"
FT   MUTAGEN         121
FT                   /note="D->A: Abolishes cleavage by caspase-6. No effect on
FT                   cleavage by granzyme B."
FT                   /evidence="ECO:0000269|PubMed:11802788"
FT   MUTAGEN         123
FT                   /note="D->A: Abolishes cleavage by caspase-6 and granzyme
FT                   B."
FT                   /evidence="ECO:0000269|PubMed:11802788"
FT   HELIX           1230..1232
FT                   /evidence="ECO:0007829|PDB:5O75"
FT   TURN            1235..1237
FT                   /evidence="ECO:0007829|PDB:3L1X"
FT   STRAND          1242..1246
FT                   /evidence="ECO:0007829|PDB:5O75"
FT   TURN            1248..1250
FT                   /evidence="ECO:0007829|PDB:2KRE"
FT   STRAND          1252..1254
FT                   /evidence="ECO:0007829|PDB:5O75"
FT   HELIX           1255..1264
FT                   /evidence="ECO:0007829|PDB:5O75"
FT   TURN            1269..1271
FT                   /evidence="ECO:0007829|PDB:5O75"
FT   HELIX           1277..1279
FT                   /evidence="ECO:0007829|PDB:5O75"
FT   HELIX           1284..1294
FT                   /evidence="ECO:0007829|PDB:5O75"
FT   TURN            1296..1298
FT                   /evidence="ECO:0007829|PDB:2KRE"
SQ   SEQUENCE   1302 AA;  146185 MW;  6BAA80984B03E43B CRC64;
     MEELSADEIR RRRLARLAGG QTSQPTTPLT SPQRENPPGP PIAASAPGPS QSLGLNVHNM
     TPATSPIGAS GVAHRSQSSE GVSSLSSSPS NSLETQSQSL SRSQSMDIDG VSCEKSMSQV
     DVDSGIENME VDENDRREKR SLSDKEPSSG PEVSEEQALQ LVCKIFRVSW KDRDRDVIFL
     SSLSAQFKQN PKEVFSDFKD LIGQILMEVL MMSTQTRDEN PFASLTATSQ PIAAAARSPD
     RNLLLNTGSN PGTSPMFCSV ASFGASSLSS LYESSPAPTP SFWSSVPVMG PSLASPSRAA
     SQLAVPSTPL SPHSAASGTA AGSQPSSPRY RPYTVTHPWA SSGVSILSSS PSPPALASSP
     QAVPASSSRQ RPSSTGPPLP PASPSATSRR PSSLRISPSL GASGGASNWD SYSDHFTIET
     CKETDMLNYL IECFDRVGIE EKKAPKMCSQ PAVSQLLSNI RSQCISHTAL VLQGSLTQPR
     SLQQPSFLVP YMLCRNLPYG FIQELVRTTH QDEEVFKQIF IPILQGLALA AKECSLDSDY
     FKYPLMALGE LCETKFGKTH PVCNLVASLR LWLPKSLSPG CGRELQRLSY LGAFFSFSVF
     AEDDVKVVEK YFSGPAITLE NTRVVSQSLQ HYLELGRQEL FKILHSILLN GETREAALSY
     MAAVVNANMK KAQMQTDDRL VSTDGFMLNF LWVLQQLSTK IKLETVDPTY IFHPRCRITL
     PNDETRVNAT MEDVNDWLTE LYGDQPPFSE PKFPTECFFL TLHAHHLSIL PSCRRYIRRL
     RAIRELNRTV EDLKNNESQW KDSPLATRHR EMLKRCKTQL KKLVRCKACA DAGLLDESFL
     RRCLNFYGLL IQLLLRILDP AYPDITLPLN SDVPKVFAAL PEFYVEDVAE FLFFIVQYSP
     QALYEPCTQD IVMFLVVMLC NQNYIRNPYL VAKLVEVMFM TNPAVQPRTQ KFFEMIENHP
     LSTKLLVPSL MKFYTDVEHT GATSEFYDKF TIRYHISTIF KSLWQNIAHH GTFMEEFNSG
     KQFVRYINML INDTTFLLDE SLESLKRIHE VQEEMKNKEQ WDQLPRDQQQ ARQSQLAQDE
     RVSRSYLALA TETVDMFHIL TKQVQKPFLR PELGPRLAAM LNFNLQQLCG PKCRDLKVEN
     PEKYGFEPKK LLDQLTDIYL QLDCARFAKA IADDQRSYSK ELFEEVISKM RKAGIKSTIA
     IEKFKLLAEK VEEIVAKNAR AEIDYSDAPD EFRDPLMDTL MTDPVRLPSG TIMDRSIILR
     HLLNSPTDPF NRQTLTESML EPVPELKEQI QAWMREKQNS DH
//
